|
BRWD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.1626000162579E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.42530000024621E-07 |
| Normal-vs-Stage2 |
2.19589999999048E-05 |
| Normal-vs-Stage3 |
3.17860004983572E-09 |
| Normal-vs-Stage4 |
1.20380372337081E-11 |
| Stage1-vs-Stage2 |
6.412200E-01 |
| Stage1-vs-Stage3 |
3.857700E-02 |
| Stage1-vs-Stage4 |
2.787400E-04 |
| Stage2-vs-Stage3 |
3.424200E-01 |
| Stage2-vs-Stage4 |
3.269700E-02 |
| Stage3-vs-Stage4 |
1.299830E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.0956999469135E-09 |
| Normal-vs-AfricanAmerican |
7.455000E-03 |
| Normal-vs-Asian |
2.56690002586879E-09 |
| Caucasian-vs-AfricanAmerican |
3.327400E-01 |
| Caucasian-vs-Asian |
3.104000E-01 |
| AfricanAmerican-vs-Asian |
2.312000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.7893004813443E-10 |
| Normal-vs-Female |
1.49590000386723E-08 |
| Male-vs-Female |
5.251800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.3869999955557E-08 |
| Normal-vs-Age(41-60Yrs) |
7.72999999565371E-08 |
| Normal-vs-Age(61-80Yrs) |
2.31769999858855E-08 |
| Normal-vs-Age(81-100Yrs) |
1.698850E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.882400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.425600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.773600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.049200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.734400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.895400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.802860E-04 |
| Classical-VS-Follicular |
9.554000E-01 |
| Classical-VS-Other |
7.852400E-01 |
| Classical-VS-Normal |
6.5513000024886E-08 |
| Tall-VS-Follicular |
1.844880E-03 |
| Tall-VS-Other |
1.256390E-01 |
| Tall-VS-Normal |
3.57209817281046E-11 |
| Follicular-VS-Other |
7.942000E-01 |
| Follicular-VS-Normal |
2.43249999999362E-05 |
| Other-VS-Normal |
1.709860E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.58109999934564E-08 |
| Normal-vs-N1 |
1.62229996103491E-09 |
| N0-vs-N1 |
1.213190E-01 |
|
|
